Hemas Holdings PLC


Investor Presentation- Q3 FY24/25

ever are



Who We Are

Established in 1948, with a purpose of empowering families to live a better tomorrow, Hemas Holdings is one of Sri Lanka's leading conglomerates listed in the Colombo Stock Exchange with focused interest in Consumer Brands and Healthcare.



Implications of Key Macro Economic Parameters on Hemas

Interest Rates

"Continued decline in AWPLR was witnessed during the year easing the pressure on finance cost to a certain extent"

-3.5%

AWPLR YoY change monthly rate (Dec 2024 vs Dec 2023)

Deflation

"Deflation was primarily driven by food category"



YoY change (Dec 2024 vs Dec 2023)

Stable Exchange Rates

"The Rupee strengthened further, positively impacting RM costs and import expenditure for key BUs"

9.7%

YoY change (Dec 2024 vs Dec 2023)

Tax Reforms

"Adverse impact of changes to the VAT laws continues to deteriorate consumer spending capacity "

18% VAT Rate With effect from January 2024 1.2 Mn Personal

Personal tax relief threshold

Global Commodity prices

"Prices of key commodities saw an increasing trend, especially Palm Oil, and this is expected to exert pressure on margins"

 44.0%
 0.8%

 Palm oil
 Crude Oil

 YoY change (Dec 2024 vs Dec 2023)

Corporate Governance



BOM (Board of Management)

Consists of the senior leadership team of 11 members - Heads of our 6 businesses and 5 leaders from Corporate Office. BOM is responsible for formulation and implementation of Group strategic plan and ensures that the Group works in a collaborative and high-performance manner not-withstanding the circumstances and challenges the Group faces.

The Board Takes overall responsibility for the performance and affairs of the Company and the Group

Board Subcommittees

Ensures in-depth focus on delegated matters




Group CEO


Leads the Executive Management team. Responsible for strategy development, implementation and Group performance



How Do We Bring Purpose to Life



Group Performance (Annual)



Long Range Plan : Key Strategic Pillars

Refreshing the portfolio

Consumer Brands aims to expand its presence in the Personal Care and Beauty categories, while hospitals focus on increasing bed capacity in tertiary care. High growth spaces

Pursuing scalable opportunities across South Asia and East Africa and Diversify the service offerings of the Mobility Segment to become an integrated player. successful turnaround

Morison will pivot to branded pharmaceuticals in cardiac, diabetes, and complementary spaces.

Enhancing efficiencies

Enhance efficiency and market position in Pharmaceutical Distribution, capture new consumers in Learning, and strengthen preferred partner status in Mobility.

Long Range Plan : Key Focus Areas



- Invest in complementary Hair and Beauty care, focus on local consumer needs, and drive household penetration in essentials like sanitary napkins.
- Implement a Bangladesh-focused strategy for affordability and access and enhance personal care offerings by leveraging extensive reach.
- Enhance efficiencies with digital transformation and leaner manufacturing and expand into non-stationery school-related categories using the Atlas brand.



- Shift focus to growing the Morison brand in cardiac, diabetes, and complementary medication, while enhancing manufacturing excellence at the Homagama facility.
- Optimise working capital and implement digital transformation to boost efficiency and cash flow, while commercialising new Principals in emerging therapeutic areas.
- Transform into a tertiary healthcare provider by expanding specialties and bed capacity and implement a seamless connected care model using digital technology.

- Continue to strengthen a lean business model
- Obtaining the required capacity/capabilities whilst leveraging on the Group's appeal as a "partner of choice"
- Build a holistic proposition, to current and prospective principals.

Awards and Recognitions



Corporate Citizens in Sri Lanka

Hemas was recognized as one of the Top 10 Best Corporate Citizens at the prestigious Best Corporate Citizen Sustainability Awards 2024, organized by the Ceylon Chamber of Commerce, underscoring its unwavering commitment to sustainable business practices and impactful environmental and social initiatives.

Hospital Management Asia Awards 2024

EXCELLENCE WINNER PATIENT EXPERIENCE IMPROVEMENT

Hemas Hospitals (Sri Lanka) Cash Discharge process time reduction at Hemas Hospitals Thalawathugoda



Hemas Hospitals has been recognized with prestigious the Excellence Business Award at the Asian Hospital Management Awards in Bali where it was lauded for its project outstanding focused on enhancing the patient experience. The project aimed to address a critical industry pain point in delays hospital discharge processes.

New Product Launches During the Quarter

Personal Care



Vivya Sunscreen 50 ml



Vivya Vitamin C range of products



Velvet Body wash Naturals range – Avocado and Coconut milk based

Pharmaceuticals Manufacturing



CliniMor tablets (Cilnidipine) 5 mg



Velvet soap - Rose & Milk



Velvet soap – Milk and Almond



Velvet soap - Orange




Velvet soap – Sandal and Curd



CliniMor tablets (Cilnidipine) 10 mg

Financial Snapshot

9M contribution to the Group




9M Performance FY 25 vs FY24

Reve BIT

Mobility


EBIT by Sector (Rs. Mn)




Healthcare Consumer Mobility Other

Monthly Net Average EPS ROCE AWPLR \$/Rs Earnings Gearing Revenue EBIT **LKR** LKR LKR LKR 24.3% 6.1% 292.6 8.9% 9.18 5.5 Bn 9.9 Bn 87.6 Bn 3.1 pts -9.0 pts -9.7% -3.5 pts 20.8 % 20.9 % 12.5 % -2.8%

Sector Performance Summary – Q3 FY 2024-25





Continuing Operation EPS – Q3 FY 2024-25

EPS Walk (LKR Per Share)





Capital Employed – FY 2024-25

Sector Efficiency Capital Employed, ROCE, and EBIT by Sector



Note: The size of the circle indicates the EBIT values

The 'other segment' includes the corporate office and remaining leisure assets

Consumer Brands

Home and Personal Care - Sri Lanka

Home and Personal Care - International

Learning Segment






Consumer Brands

Contribution to Group

41% **Revenue %** 9M FY25 42% 9M FY24 **EBITDA %** 49% 9M FY25 9M FY24 54% Capital Employed % 32% 31% FY25 FY24




Sector Performance – 9M FY 2024-25

Key Highlights

- The appreciation of the Rupee and the decline in commodity prices have intensified competition within the industry, with several players offering a variety of consumer, shopper and trade promotions.
- The Learning segment continued to be impacted by price competition and seasonality factors
- Bangladesh inflation continued to rise, reaching 10.9 % in December with food inflation particularly affecting households

Home and Personal Care – Sri Lanka



Home and Personal Care – International



Home and Personal Care – Sri Lanka and International

<u>Sri Lanka</u>

Revenue

- The personal care segment experienced volume-led growth
- The Home care segment saw a decline in market share due to increased demand for generic products in price-sensitive segments.
- The drive to introduce innovative offerings continued, with the launch of Vivya sunscreen and Vitamin C range, as well as Velvet body wash Naturals range. Additionally, the relaunch of Velvet soap, with improved product attributes and packaging, has gained strong momentum

Profitability


 While the GP margins were maintained, profitability was negatively impacted by higher advertising, promotion and marketing costs.

Outlook

- Championing local ingredients, cultivating purpose-driven brands and entering in to underpenetrated areas would be the priorities for the business.
- Rising commodity prices will have a negative impact on input costs.



International Segment Revenue as a % of total HPC Segment



International

Revenue

- Revenue was impacted by by rising inflation and increased price sensitivity, which have led many consumers to seek more affordable alternatives.
- 'Kumarika', the flagship Value-Added Hair Oil (VAHO) product has successfully maintained its market share, backed by the product's strong customer loyalty and consistent repeat purchases


Profitability


 Profitability increased due to various cost rationalisation initiatives undertaken during the quarter.

Outlook

 Rising inflation and the prevailing political uncertainty have negatively impacted the consumer sentiment. The interim government is taking steps to control inflation and minimise commodity shortages

Learning Segment





Revenue

 In response heightened competition from new entrants offering products at lower price points and varying quality, several initiatives were launched to increase awareness and create a unique and innovative point of difference, such as the re-launch of its "Innovate" range.

Profitability

 Growth in revenue, coupled with Increased efforts on efficiency improvement and cost saving initiatives contributed increased operating profits.

Outlook

- Several initiatives were launched to create a unique and innovative point of difference
- Pursue distribution partnerships with international players and expand the export footprint.
- Explore opportunities in related spaces.

Healthcare Sector


Pharmaceutical Import, Marketing and Distribution

Pharmaceutical Manufacturing

Hospitals




Healthcare




Sector Performance – 9M FY 2024-25


Key Highlights

- The Healthcare industry has been gaining momentum and recovering from the downturn experienced during the economic crisis.
- The trend of consumers increasingly seeking more affordable options continued throughout the quarter under review.
- The EBITDA witnessed strong growth due to increased revenue and efficiency measures.



Pharmaceutical Import, Marketing, Distribution and Pharmaceutical Manufacturing







Outlook

- Further extending the branded generics portfolio to create a " Sri Lankan Brand" will be a key priority for the Manufacturing Arm of the Sector while ensuring availability and increasing the offering by onboarding new Principles will drive the Distribution Arm.
- Extension of the buyback agreement with new orders already received, will boost revenues and plant uilisation.

Hospitals





Revenue

 While outpatient revenue has seen a steady increase, inpatient revenue experienced a decline due to lower admissions, which was a trend observed across the market.

Profitability

• GP & EBITDA margins improved owing to the efficiency measures that were implemented.

Outlook

 Plans for expansion at the two hospitals in Wattala and Thalawathugoda are progressing, with the planned acquisition of land for the expansion of the Thalawathugoda hospital being completed, marking a key milestone in our growth strategy.


IP revenue mix	Q3FY24	Q4FY24	Q1FY25	Q2FY25	Q3FY25
	54%	49%	55%	53%	48%

Mobility Sector

Maritime







Sector Performance – 9M FY 2024-25

The Maritime sector witnessed an ٠ increase in both freight rates and volumes in the import and export operations compared to the previous year. In the Aviation segment, cargo revenue grew due to higher yields and expanded market share Emirates SkyCargo (CMB) was recognized for its outstanding service and major contributions to Sri Lanka's logistics sector, receiving the prestigious Gold Award in the Airline Category at the 2024 National Logistics Awards, hosted by the Sri Lanka Logistics and Freight Forwarders

Association

Key Highlights

Environmental Agenda 2030

Encouraging responsible plastic consumption



1.2 Million+ Kgs Collection of plastic to date




Protecting Sri Lankan endemism



15 Critically endangered endemic species

Social Impact : Focus Areas

Q3 FY 25: 49,000+ Families Empowered







Empowering Vulnerable Communities

- Empowering women
 with entrepreneurship,
 knowledge-building
 and skills development.
- Empowering children with disabilities to reach their full potential.
- Distribution of dry rations and other essentials for vulnerable communities.

Social Impact : 49,000+ Families Empowered



Sustainability Performance- Q1 24-25 VS Q1 23-24



Key Priorities

Corporate Priorities

Accelerating the M&A opportunities

Driving digital transformation

Strategic cost savings and maintaining optimum liquidity under working capital management initiatives



Consumer

BU Priorities

Healthcare

Focus on Personal care, Beauty and wellness with a drive for premiumisation and exploring underpenetrated Markets

Strengthening value prepositions to grow market share

Accelerate exports and international expansion

Increase efficiency via digitisation initiatives

Build the Morison brand by capitalising on existing launches and developing a strong Sri Lankan private brand of generics

Invest in new business commercialisation, growth in under indexed TCs, adjacencies and diagnostic business

Focus on anchor specialties and expansions in the Hospitals business

Digitalisation and effective working capital management

Disclaimer

The material in this presentation has been prepared by Hemas Holdings PLC ("Hemas") and is general background information about Hemas' activities current as at the date of this presentation. This information is given in summary form and does not purport to be complete. Information in this presentation, including forecast financial information, should not be considered as advice or a recommendation to investors or potential investors in relation to holding, purchasing or selling securities or other financial products or instruments and does not take into account your particular investment objectives, financial situation or needs. Before acting on any information you should consider the appropriateness of the information having regard to these matters, any relevant offer document and in particular, you should seek independent financial advice. All securities and financial product or instrument transactions involve risks, which include (among others) the risk of adverse or unanticipated market, financial or political developments and, in international transactions, currency risk.

This presentation may contain forward looking statements including statements regarding our intent, belief or current expectations with respect to Hemas' businesses and operations, market conditions, results of operation and financial condition, capital adequacy, specific provisions and risk management practices. Hemas does not undertake any obligation to publicly release the result of any revisions to these forward-looking statements to reflect events or circumstances after the date hereof to reflect the occurrence of unanticipated events. While due care has been used in the preparation of forecast information, actual results may vary in a materially positive or negative manner. Forecasts and hypothetical examples are subject to uncertainty and contingencies outside Hemas' control. Past performance is not a reliable indication of future performance. Unless otherwise specified all information is for the quarter ended 31 December 2024.